All currency values in $ millions unless otherwise noted
Scroll
| Income Statement | TTM | MAR 2026 | MAR 2025 | MAR 2024 | MAR 2023 | MAR 2022 |
|---|---|---|---|---|---|---|
| Revenues | ||||||
| Revenue | $250 | $249 | $241 | $216 | $219 | $184 |
| Cost of Revenue | $89 | $91 | $90 | $83 | $85 | $75 |
| Gross Profit | $160 | $158 | $151 | $133 | $134 | $109 |
| Operating Expenses | ||||||
| Selling & Marketing | $40 | $41 | $42 | $39 | $37 | $28 |
| General & Administrative | $78 | $79 | $73 | $73 | $72 | $60 |
| Research & Development | $20 | $20 | $20 | $19 | $20 | $16 |
| Provision for Doubtful Accounts | – | $1 | $0 | $1 | $1 | $0 |
| Total Operating Expenses | $138 | $140 | $135 | $405 | $130 | $104 |
| Operating Income | $22 | $19 | $16 | -$272 | $3 | $5 |
| Non-Operating | ||||||
| Net Interest Expense | -$11 | -$11 | -$12 | -$6 | -$5 | -$4 |
| Other Non-Operating Income (Expense) | -$2 | $4 | $1 | $2 | $1 | $3 |
| EBT (Earnings Before Tax) | $9 | $12 | $6 | -$276 | -$0 | $4 |
| Income Tax Expense | $5 | $5 | $8 | -$21 | -$1 | $2 |
| Earnings from Continuing Ops | – | $12 | $6 | -$276 | -$0 | – |
| Net Income | ||||||
| Net Income | $5 | $7 | -$2 | -$254 | $1 | $2 |
| Per Share Data | ||||||
| Revenue Per Share | $43.38 | $44.77 | $44.45 | $40.14 | $40.87 | $34.55 |
| EPS (Basic) | $0.85 | $1.22 | -$0.36 | -$47.20 | $0.17 | $0.36 |
| EPS (Diluted) | $0.85 | $1.21 | -$0.36 | -$47.20 | $0.17 | $0.35 |
| Weighted Avg Shares (Basic) | 5.7M | 5.5M | 5.4M | 5.4M | 5.3M | 5.2M |
| Weighted Avg Shares (Diluted) | 5.8M | 5.6M | 5.4M | 5.4M | 5.4M | 5.3M |
| Shares Outstanding | 5.8M | 5.6M | 5.4M | 5.4M | 5.4M | 5.3M |
| Dividends Per Share | $0.64 | $0.64 | $0.64 | $0.64 | $0.64 | $0.64 |
Mesa Laboratories (MLAB) financials: revenue, profit and margins
Mesa Laboratories (MLAB) generated about $250 million in revenue and $5 million in net income (a 1.9% net margin) over the trailing twelve months, growing at roughly 13.2% a year. Figures are from SEC filings; this is analysis, not investment advice.
Frequently asked
What is Mesa Laboratories's (MLAB) revenue?+
Mesa Laboratories generated about $250 million in revenue over the trailing twelve months. Revenue has grown at roughly 13.2% a year over the past five years. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.
Is Mesa Laboratories profitable?+
Yes, Mesa Laboratories reported about $5 million in net income over the trailing twelve months, a net profit margin of roughly 1.9%. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
What are Mesa Laboratories's profit margins?+
Mesa Laboratories runs a gross margin of about 64.2%, an operating margin of about 9.0%, a net margin of about 1.9%. Margins show how much of each sales dollar a company keeps at each stage. Stable or rising margins usually signal pricing power and cost discipline; falling margins are worth investigating. See the multi-year trend on this tab.
How fast is Mesa Laboratories growing?+
Mesa Laboratories's revenue has compounded at roughly 13.2% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside MLAB's margins and free cash flow. This is analysis from SEC filings, not investment advice.
SourceFinancial statements computed from the 10-Q filed 3 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 3 Oct 2026. How this is calculated.
Fiscal year ends Mar.
Peers
Industrial Instruments For Measurement, Display, and Control · Pick stocks to compare with MLAB
Held by ETFs
MLAB is in 26 US ETFs. The largest of them, with MLAB's weight in each:
Vanguard Health Care ETFVHT0.01%of the fund
iShares Russell 2000 Growth ETFIWO0.05%of the fund
Dimensional U.S. Targeted Value ETFDFAT0.02%of the fund
Fidelity Enhanced Small Cap ETFFESM0.13%of the fund
Avantis U.S. Small Cap Equity ETFAVSC0.05%of the fund
Spot a number that looks wrong? Check it in MLAB's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing MLAB
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.